echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Hydroxychloroquine can reduce autoimmune hepatitis!

    Hydroxychloroquine can reduce autoimmune hepatitis!

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Autoimmune hepatitis (AIH) is a serious inflammatory liver disease
    The current standard of care for autoimmune hepatitis is corticosteroids alone or in combination with azathioprine, which often has serious adverse effects
    Hydroxychloroquine (HCQ) is a derivative of the heterocyclic aromatic compound quinoline and has long been used as an antimalarial drug
    Currently, it is an excellent candidate for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

    Treatment with HCQ has been reported to reduce liver damage
    in COVID-19 patients.
    Other studies have found that HCQ may have inhibitory effects
    on immune cell infiltration and activation of joint inflammation.

    Schematic diagram of the role and mechanism of HCQ in the treatment of autoimmune hepatitis:

    HCQ improved liver pathological damage and inflammatory infiltration in mice with autoimmune hepatitis:

    The central objective of this study is to investigate the therapeutic efficacy and inflammatory immune molecular mechanisms
    of HCQ in experimental autoimmune hepatitis (AIH).
    HCQ treatment improves liver pathological injury, inflammatory infiltration, and promotes downregulation
    of CD8 T cell differentiation in regulatory T cells and S-100 antigen-induced AIH mice.
    In vitro, HCQ also inhibits the secretion of pro-inflammatory cytokines (IFN-γ, TNF-α and IL-12) and promotes the secretion
    of anti-inflammatory cytokines (TGF-β+1).
    HCQ mainly impairs T cell lipid metabolism, but does not promote glycolysis and promotes T cell lipid metabolism differentiation and function
    Mechanically, HCQ downregulates GRK2 membrane translocation in T cells, inhibits GRK2-PI3K interaction to reduce PI3K recruitment to the membrane, and then inhibits phosphorylation of PI3K-AKT-mTOR signaling
    Pretreatment of T cells with paroxetine, a GRK2 inhibitor, interfered with the HCQ effect
    on T cells.
    HCQ also reversed the activation
    of the PI3K-AKT axis by 740 Y-P (PI3K agonist).
    At the same time, HCQ inhibits PI3K-AKT-mTOR, JAK2-STAT3-SOCS3 and increases AMPK signaling
    in the liver and T cells of AIH mice.

    Lipid metabolism in T cells is controlled by HCQ:

    HCQ inhibits the activation of JAK2-STAT3-SOCS3 and promotes phosphorylation of AMPK in T lymphocytes:

    In summary, HCQ has a specific and effective therapeutic effect on autoimmune hepatitis and concomitant liver injury, which is attributed to HCQ acting on GRK2 translocation, inhibiting PI3K-AKT and inflammation-related JAK2-STAT3 signals related to T lymphocyte metabolism, thereby regulating lipid metabolism of T cell function to regulate T lymphocyte differentiation and function


    References: Jin C, Gao BB, Zhou WJ, Zhao BJ, Fang X, Yang CL, Wang XH, Xia Q, Liu TT.
    Hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes.
    Front Pharmacol.
    2022 Sep 15; 13:972397.
    doi: 10.
    PMID: 36188529; PMCID: PMC9520598.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.